A pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue SUPPL 1, 2013, Pages 85-92

  Wang, Lifeng ^a   Li, Jin ^a   Liu, Honghong ^a,b   Li, Yuanyuan ^a   Fu, Junliang ^a   Sun, Ying ^a   Xu, Ruonan ^a   Lin, Hu ^a   Wang, Siyu ^a   Lv, Sa ^a   Chen, Liming ^a   Zou, Zhengsheng ^a   Li, Baosen ^a   Shi, Ming ^a   Zhang, Zheng ^a   Wang, Fu Sheng ^a,b  

^a BEIJING 302 HOSPITAL   (China)

^b MEDICAL SCHOOL OF CHINESE PLA   (China)

Author keywords

Immune regulation; Mesenchymal stem cell; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; MITOCHONDRION ANTIBODY; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIBODY TITER; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD COMPONENT THERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; INTERNATIONAL NORMALIZED RATIO; INTERNATIONAL PROGNOSTIC INDEX; MALE; MESENCHYMAL STEM CELL; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; UMBILICAL CORD DERIVED MESENCHYMAL STEM CELL TRANSFUSION;

EID: 84880411961     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12029     Document Type: Review

References (36)

1. Lindor KD, Gershwin ME, Poupon R etal. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
2. Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-720.
3. Leuschner M, Dietrich CF, You T etal. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000; 46: 121-126.
4. Angulo P, Patel T, Jorgensen RA etal. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32: 897-900.
5. Angulo P, Jorgensen RA, Keach JC etal. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31: 318-323.
6. Stojakovic T, Putz-Bankuti C, Fauler G etal. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46: 776-784.
7. Kaplan MM, Bonder A, Ruthazer R, Bonis PA. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig. Dis. Sci. 2010; 55: 3207-3217.
8. Tsuda M, Moritoki Y, Lian ZX etal. Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Hepatology 2012; 55: 512-521.
9. Yin YF, Zhang X. B cell depletion in treating primary biliary cirrhosis: pros and cons. World J. Gastroenterol. 2012; 18: 3938-3940.
10. Sanchez-Ramos J, Song S, Cardozo-Pelaez F etal. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp. Neurol. 2000; 164: 247-256.
11. Schwartz RE, Reyes M, Koodie L etal. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest. 2002; 109: 1291-1302.
12. Caplan AI, Bruder SP. Mesenchymal stem cells: building blocks for molecular medicine in the 21st century. Trends Mol. Med. 2001; 7: 259-264.
13. Hu AB, He XS, Cai JY, Zheng QC. Directional differentiation of embryonic stem cells into biliary epithelium cells in vitro: an experiment with mice. Zhonghua Yi Xue Za Zhi 2005; 85: 2550-2553.
14. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
15. Deuse T, Stubbendorff M, Tang-Quan K etal. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011; 20: 655-667.
16. Jiang XX, Zhang Y, Liu B etal. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126.
17. Sotiropoulou PA, Perez SA, Gritzapis AD etal. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
18. Kestendjieva S, Kyurkchiev D, Tsvetkova G etal. Characterization of mesenchymal stem cells isolated from the human umbilical cord. Cell Biol. Int. 2008; 32: 724-732.
19. Sun L, Wang D, Liang J etal. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010; 62: 2467-2475.
20. Liu Y, Mu R, Wang S etal. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res. Ther. 2010; 12: R210.
21. Ma L, Zhou Z, Zhang D etal. Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thromb. Haemost. 2012; 107: 937-950.
22. Zhang Z, Lin H, Shi M etal. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J. Gastroenterol. Hepatol. 2012; 27 (Suppl. 2): 112-120.
23. Shi M, Zhang Z, Xu R etal. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl. Med. 2012; 1: 725-731.
24. Wood NJ. Primary biliary cirrhosis: fenofibrate plus UDCA promising for incomplete responders to UDCA. Nat. Rev. Gastroenterol. Hepatol. 2011; 8: 63.
25. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011; 377: 1600-1609.
26. Jacob DA, Bahra M, Schmidt SC etal. Mayo risk score for primary biliary cirrhosis: a useful tool for the prediction of course after liver transplantation? Ann. Transplant. 2008; 13: 35-42.
27. Dickson ER, Grambsch PM, Fleming TR etal. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10: 1-7.
28. Abbas G, Jorgensen RA, Lindor KD. Fatigue in primary biliary cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 2010; 7: 313-319.
29. Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J. Gastroenterol. Hepatol. 2012; 27: 1150-1158.
30. Fisk JD, Ritvo PG, Ross L etal. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 1994; 18 (Suppl. 1): S79-83.
31. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. Br. J. Dermatol. 2010; 162: 587-593.
32. Talbot TL, Schmitt JM, Bergasa NV etal. Application of piezo film technology for the quantitative assessment of pruritus. Biomed. Instrum. Technol. 1991; 25: 400-403.
33. Jin Q, Moritoki Y, Lleo A etal. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012; 55: 1495-1506.
34. Kim WR, Poterucha JJ, Jorgensen RA etal. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation. Hepatology 1997; 26: 22-26.
35. Roma MG, Toledo FD, Boaglio AC etal. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications. Clin. Sci. 2011; 121: 523-544.
36. Solá S, Aranha MM, Steer CJ, Rodrigues CM. Game and players: mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr. Issues Mol. Biol. 2007; 9: 123-138.